Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators

Ingeborg A. Brouwer, Merritt H. Raitt, Carla Dullemeijer, Dale Kraemer, Peter L. Zock, Cynthia Morris, Martijn B. Katan, William E. Connor, John A. Camm, Evert G. Schouten, John McAnulty

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

Aims: To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials.Methods and resultsWe searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95 CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79).ConclusionThese findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies.

Original languageEnglish (US)
Pages (from-to)820-826
Number of pages7
JournalEuropean Heart Journal
Volume30
Issue number7
DOIs
StatePublished - Apr 2009

Fingerprint

Implantable Defibrillators
Fish Oils
Tachycardia
Cardiac Arrhythmias
Omega-3 Fatty Acids
Ventricular Fibrillation
Ventricular Tachycardia
Meta-Analysis
Unsaturated Fatty Acids
Placebos
Coronary Artery Disease
Fishes
Randomized Controlled Trials
Databases
Pathology
Incidence

Keywords

  • Arrhythmia
  • Fish oil
  • ICD
  • Omega-3

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. / Brouwer, Ingeborg A.; Raitt, Merritt H.; Dullemeijer, Carla; Kraemer, Dale; Zock, Peter L.; Morris, Cynthia; Katan, Martijn B.; Connor, William E.; Camm, John A.; Schouten, Evert G.; McAnulty, John.

In: European Heart Journal, Vol. 30, No. 7, 04.2009, p. 820-826.

Research output: Contribution to journalArticle

Brouwer, IA, Raitt, MH, Dullemeijer, C, Kraemer, D, Zock, PL, Morris, C, Katan, MB, Connor, WE, Camm, JA, Schouten, EG & McAnulty, J 2009, 'Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators', European Heart Journal, vol. 30, no. 7, pp. 820-826. https://doi.org/10.1093/eurheartj/ehp003
Brouwer, Ingeborg A. ; Raitt, Merritt H. ; Dullemeijer, Carla ; Kraemer, Dale ; Zock, Peter L. ; Morris, Cynthia ; Katan, Martijn B. ; Connor, William E. ; Camm, John A. ; Schouten, Evert G. ; McAnulty, John. / Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators. In: European Heart Journal. 2009 ; Vol. 30, No. 7. pp. 820-826.
@article{013d3a5dd58045848232500a815e607d,
title = "Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators",
abstract = "Aims: To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials.Methods and resultsWe searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95 CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79).ConclusionThese findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies.",
keywords = "Arrhythmia, Fish oil, ICD, Omega-3",
author = "Brouwer, {Ingeborg A.} and Raitt, {Merritt H.} and Carla Dullemeijer and Dale Kraemer and Zock, {Peter L.} and Cynthia Morris and Katan, {Martijn B.} and Connor, {William E.} and Camm, {John A.} and Schouten, {Evert G.} and John McAnulty",
year = "2009",
month = "4",
doi = "10.1093/eurheartj/ehp003",
language = "English (US)",
volume = "30",
pages = "820--826",
journal = "European Heart Journal",
issn = "0195-668X",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Effect of fish oil on ventricular tachyarrhythmia in three studies in patients with implantable cardioverter defibrillators

AU - Brouwer, Ingeborg A.

AU - Raitt, Merritt H.

AU - Dullemeijer, Carla

AU - Kraemer, Dale

AU - Zock, Peter L.

AU - Morris, Cynthia

AU - Katan, Martijn B.

AU - Connor, William E.

AU - Camm, John A.

AU - Schouten, Evert G.

AU - McAnulty, John

PY - 2009/4

Y1 - 2009/4

N2 - Aims: To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials.Methods and resultsWe searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95 CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79).ConclusionThese findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies.

AB - Aims: To determine the effects of omega-3 polyunsaturated fatty acids (omega-3 PUFAs) from fish on the incidence of recurrent ventricular arrhythmia in implantable cardioverter defibrillator (ICD) patients by combining results from published trials.Methods and resultsWe searched in the Medline, EMBASE, and Cochrane databases and performed a meta-analysis on all three available trials on fish oil and ventricular arrhythmia. Furthermore, we pooled individual data of two of these randomized, double-blind, placebo-controlled trials (Raitt et al. Fish oil supplementation and risk of ventricular tachycardia and ventricular fibrillation in patients with implantable defibrillators: a randomized controlled trial. JAMA 2005;293:2884-2891 and Brouwer et al. Effect of fish oil on ventricular tachyarrhythmia and death in patients with implantable cardioverter defibrillators: the Study on Omega-3 Fatty Acids and Ventricular Arrhythmia (SOFA) randomized trial. JAMA 2006;295:2613-2619). The main outcome was time to first confirmed ventricular fibrillation (VF) or ventricular tachycardia (VT) combined with death for the meta-analysis, and time to first spontaneous confirmed VF or VT for the pooled analysis. The meta-analysis (n = 1148) showed no convincing protective effect of fish oil (RR 0.90; 95 CI 0.67-1.22). The hazard ratio for the subgroup of patients with coronary artery disease at baseline (0.79; 0.60-1.06) tended towards a protective effect. The pooled analysis (n = 722) showed that time to appropriate ICD intervention was similar for fish oil and placebo treatment (log-rank P = 0.79).ConclusionThese findings do not support a protective effect of omega-3 PUFAs from fish oil on cardiac arrhythmia in all patients with an ICD. Current data neither prove nor disprove a beneficial or a detrimental effect for subgroups of patients with specific underlying pathologies.

KW - Arrhythmia

KW - Fish oil

KW - ICD

KW - Omega-3

UR - http://www.scopus.com/inward/record.url?scp=64849110630&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=64849110630&partnerID=8YFLogxK

U2 - 10.1093/eurheartj/ehp003

DO - 10.1093/eurheartj/ehp003

M3 - Article

C2 - 19196720

AN - SCOPUS:64849110630

VL - 30

SP - 820

EP - 826

JO - European Heart Journal

JF - European Heart Journal

SN - 0195-668X

IS - 7

ER -